{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:39Z","timestamp":1791925659263,"version":"4.3.4"},"reference-count":78,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic will be remembered as one of the worst catastrophic events in human history. Unfortunately, no universally recognized effective therapeutic agents are currently available for the treatment of severe SARS-CoV-2 infection. In this context, the use of convalescent plasma from recovered COVID-19 patients has gained increasing interest thanks to the initially positive clinical reports. A number of mechanisms of action have been proposed for convalescent plasma, including direct neutralization and suppression of viremia, anti-inflammatory and immunomodulation effects and mitigation of the COVID-19-associated hypercoagulable state. These immune and non-immune mechanisms will be critically discussed in this narrative review.<\/jats:p>","DOI":"10.1515\/dx-2020-0161","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T17:27:36Z","timestamp":1614706056000},"page":"413-420","source":"Crossref","is-referenced-by-count":18,"title":["Potential mechanisms of action of convalescent plasma in COVID-19"],"prefix":"10.1515","volume":"8","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[{"name":"Department of Hematology and Transfusion Medicine , Carlo Poma Hospital , Mantova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Glingani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transfusion Medicine , Carlo Poma Hospital , Mantova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo Maria","family":"Liumbruno","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transfusion Medicine , Carlo Poma Hospital , Mantova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"2025121207121257052_j_dx-2020-0161_ref_001","doi-asserted-by":"crossref","unstructured":"Chen, Y, Liu, Q, Guo, D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418\u201323.","DOI":"10.1002\/jmv.25681"},{"key":"2025121207121257052_j_dx-2020-0161_ref_002","doi-asserted-by":"crossref","unstructured":"Kuiken, T, Fouchier, RA, Schutten, M, Rimmelzwaan, GF, van Amerongen, G, van Riel, D, et al.. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263\u201370.","DOI":"10.1016\/S0140-6736(03)13967-0"},{"key":"2025121207121257052_j_dx-2020-0161_ref_003","doi-asserted-by":"crossref","unstructured":"Drosten, C, G\u00fcnther, S, Preiser, W, van der Werf, S, Brodt, HR, Becker, S, et al.. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967\u201376.","DOI":"10.1056\/NEJMoa030747"},{"key":"2025121207121257052_j_dx-2020-0161_ref_004","doi-asserted-by":"crossref","unstructured":"de Groot, RJ, Baker, SC, Baric, RS, Brown, CS, Drosten, C, Enjuanes, L, et al.. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013;87:7790\u20132.","DOI":"10.1128\/JVI.01244-13"},{"key":"2025121207121257052_j_dx-2020-0161_ref_005","doi-asserted-by":"crossref","unstructured":"Peeri, NC, Shrestha, N, Rahman, MS, Zaki, R, Tan, Z, Bibi, S, et al.. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020;49:717\u201326.","DOI":"10.1093\/ije\/dyaa033"},{"key":"2025121207121257052_j_dx-2020-0161_ref_006","doi-asserted-by":"crossref","unstructured":"Mahase, E. Covid-19: WHO declares pandemic because of \u201calarming levels\u201d of spread, severity, and inaction. BMJ 2020;368:m1036.","DOI":"10.1136\/bmj.m1036"},{"key":"2025121207121257052_j_dx-2020-0161_ref_007","doi-asserted-by":"crossref","unstructured":"Boban, M. Novel corona virus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract 2020:e13868.","DOI":"10.1111\/ijcp.13868"},{"key":"2025121207121257052_j_dx-2020-0161_ref_008","doi-asserted-by":"crossref","unstructured":"Lyngbakken, MN, Berdal, JE, Eskesen, A, Kvale, D, Olsen, IC, Rueegg, CS, et al.. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun 2020;11:5284.","DOI":"10.1038\/s41467-020-19056-6"},{"key":"2025121207121257052_j_dx-2020-0161_ref_009","doi-asserted-by":"crossref","unstructured":"Wang, Y, Zhang, D, Du, G, Du, R, Zhao, J, Jin, Y, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569\u201378.","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"2025121207121257052_j_dx-2020-0161_ref_010","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19\u00a0\u2013interim WHO solidarity trial results. medRxiv 2020. https:\/\/doi.org\/10.1101\/2020.10.15.20209817.","DOI":"10.1101\/2020.10.15.20209817"},{"key":"2025121207121257052_j_dx-2020-0161_ref_011","doi-asserted-by":"crossref","unstructured":"Shen, C, Wang, Z, Zhao, F, Yang, Y, Li, J, Yuan, J, et al.. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582\u20139.","DOI":"10.1001\/jama.2020.4783"},{"key":"2025121207121257052_j_dx-2020-0161_ref_012","doi-asserted-by":"crossref","unstructured":"Casadevall, A, Dadachova, E, Pirofski, L. Passive antibody therapy for infectious diseases. Nature Microbiol Rev 2004;2:695\u2013703.","DOI":"10.1038\/nrmicro974"},{"key":"2025121207121257052_j_dx-2020-0161_ref_013","doi-asserted-by":"crossref","unstructured":"Luke, TC, Casadevall, A, Watowich, SJ, Hoffman, SL, Beigel, JH, Burgess, TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38:e66\u201373.","DOI":"10.1097\/CCM.0b013e3181d44c1e"},{"key":"2025121207121257052_j_dx-2020-0161_ref_014","doi-asserted-by":"crossref","unstructured":"Luke, TC, Kilbane, EM, Jackson, JL, Hoffman, SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006;145:599\u2013609.","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"2025121207121257052_j_dx-2020-0161_ref_015","unstructured":"Marano, G, Vaglio, S, Pupella, S, Facco, G, Catalano, L, Liumbruno, GM, et al.. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016;14:152\u20137."},{"key":"2025121207121257052_j_dx-2020-0161_ref_016","doi-asserted-by":"crossref","unstructured":"Mair-Jenkins, J, Saavedra-Campos, M, Baillie, JK, Cleary, P, Khaw, FM, Lim, WS, et al.. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80\u201390.","DOI":"10.1093\/infdis\/jiu396"},{"key":"2025121207121257052_j_dx-2020-0161_ref_017","doi-asserted-by":"crossref","unstructured":"Wooding, DJ, Bach, H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect 2020;26:1436\u201346.","DOI":"10.1016\/j.cmi.2020.08.005"},{"key":"2025121207121257052_j_dx-2020-0161_ref_018","doi-asserted-by":"crossref","unstructured":"Stevens, RW, Rivera, CG, Saleh, OA. Time to treat: applying lessons learned from other viral syndromes to SARS-CoV-2. Mayo Clin Proc Innov Qual Outcomes 2020;4:759\u201363.","DOI":"10.1016\/j.mayocpiqo.2020.09.010"},{"key":"2025121207121257052_j_dx-2020-0161_ref_019","doi-asserted-by":"crossref","unstructured":"Sun, M, Xu, Y, He, H, Zhang, L, Wang, X, Qiu, Q, et al.. A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis 2020;98:334\u201346.","DOI":"10.1016\/j.ijid.2020.06.107"},{"key":"2025121207121257052_j_dx-2020-0161_ref_020","doi-asserted-by":"crossref","unstructured":"Salazar, E, Christensen, PA, Graviss, EA, Nguyen, DT, Castillo, B, Chen, J, et al.. Treatment of Coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020;190:2290\u2013303.","DOI":"10.1016\/j.ajpath.2020.08.001"},{"key":"2025121207121257052_j_dx-2020-0161_ref_021","doi-asserted-by":"crossref","unstructured":"Perotti, C, Baldanti, F, Bruno, R, Del Fante, C, Seminari, E, Casari, S, et al.. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020;105:2834\u201340.","DOI":"10.3324\/haematol.2020.261784"},{"key":"2025121207121257052_j_dx-2020-0161_ref_022","doi-asserted-by":"crossref","unstructured":"Brown, BL, McCullough, J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci 2020;59:102790.","DOI":"10.1016\/j.transci.2020.102790"},{"key":"2025121207121257052_j_dx-2020-0161_ref_023","doi-asserted-by":"crossref","unstructured":"Simonovich, VA, Burgos Pratx, LD, Scibona, P, Beruto, MV, Vallone, MG, V\u00e1zquez, C, et al.. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med 2020 Nov 24. https:\/\/doi.org\/10.1056\/NEJMoa2031304 [Epub ahead of print].","DOI":"10.1056\/NEJMoa2031304"},{"key":"2025121207121257052_j_dx-2020-0161_ref_024","doi-asserted-by":"crossref","unstructured":"Liu, STH, Lin, HM, Baine, I, Wajnberg, A, Gumprecht, JP, Rahman, F, et al.. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med 2020;26:1708\u201313.","DOI":"10.1038\/s41591-020-1088-9"},{"key":"2025121207121257052_j_dx-2020-0161_ref_025","doi-asserted-by":"crossref","unstructured":"Agarwal, A, Mukherjee, A, Kumar, G, Chatterjee, P, Bhatnagar, T, Malhotra, P, et al.. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939.","DOI":"10.1136\/bmj.m3939"},{"key":"2025121207121257052_j_dx-2020-0161_ref_026","doi-asserted-by":"crossref","unstructured":"Chai, KL, Valk, SJ, Piechotta, V, Kimber, C, Monsef, I, Doree, C, et al.. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020;10:CD013600.","DOI":"10.1002\/14651858.CD013600.pub3"},{"key":"2025121207121257052_j_dx-2020-0161_ref_027","doi-asserted-by":"crossref","unstructured":"Rojas, M, Rodr\u00edguez, Y, Monsalve, DM, Acosta-Ampudia, Y, Camacho, B, Gallo, JE, et al.. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev 2020;19:102554.","DOI":"10.1016\/j.autrev.2020.102554"},{"key":"2025121207121257052_j_dx-2020-0161_ref_028","doi-asserted-by":"crossref","unstructured":"Stratton, CW, Tang, YW, Lu, H. Pathogenesis-directed therapy of 2019 novel coronavirus disease. J Med Virol 2021;93:1320\u201342https:\/\/doi.org\/10.1002\/jmv.26610.","DOI":"10.1002\/jmv.26610"},{"key":"2025121207121257052_j_dx-2020-0161_ref_029","doi-asserted-by":"crossref","unstructured":"Liu, Z, Xiao, X, Wei, X, Li, J, Yang, J, Tan, H, et al.. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J\u00a0Med Virol 2020;92:595\u2013601.","DOI":"10.1002\/jmv.25726"},{"key":"2025121207121257052_j_dx-2020-0161_ref_030","doi-asserted-by":"crossref","unstructured":"Connors, JM, Levy, JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033\u201340.","DOI":"10.1182\/blood.2020006000"},{"key":"2025121207121257052_j_dx-2020-0161_ref_031","doi-asserted-by":"crossref","unstructured":"Leisman, DE, Deutschman, CS, Legrand, M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020;46:1105\u20138.","DOI":"10.1007\/s00134-020-06059-6"},{"key":"2025121207121257052_j_dx-2020-0161_ref_032","doi-asserted-by":"crossref","unstructured":"Kichloo, A, Dettloff, K, Aljadah, M, Albosta, M, Jamal, S, Singh, J, et al.. COVID-19 and hypercoagulability: a review. Clin Appl Thromb Hemost 2020;26:1076029620962853.","DOI":"10.1177\/1076029620962853"},{"key":"2025121207121257052_j_dx-2020-0161_ref_033","doi-asserted-by":"crossref","unstructured":"Mackman, N, Antoniak, S, Wolberg, AS, Kasthuri, R, Key, NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol 2020;40:2033\u201344.","DOI":"10.1161\/ATVBAHA.120.314514"},{"key":"2025121207121257052_j_dx-2020-0161_ref_034","doi-asserted-by":"crossref","unstructured":"Coperchini, F, Chiovato, L, Croce, L, Magri, F, Rotondi, M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine Growth Factor Rev 2020;53:25\u201332.","DOI":"10.1016\/j.cytogfr.2020.05.003"},{"key":"2025121207121257052_j_dx-2020-0161_ref_035","doi-asserted-by":"crossref","unstructured":"Ng, H, Havervall, S, Rosell, A, Aguilera, K, Parv, K, von Meijenfeldt, FA, et al.. Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19. Arterioscler Thromb Vasc Biol 2020:ATVBAHA120315267.","DOI":"10.1161\/ATVBAHA.120.315267"},{"key":"2025121207121257052_j_dx-2020-0161_ref_036","doi-asserted-by":"crossref","unstructured":"Franchini, M, Marano, G, Cruciani, M, Mengoli, C, Pati, I, Masiello, F, et al.. COVID-19-associated coagulopathy. Diagnosis (Berl) 2020;7:357\u201363.","DOI":"10.1515\/dx-2020-0078"},{"key":"2025121207121257052_j_dx-2020-0161_ref_037","doi-asserted-by":"crossref","unstructured":"Walls, AC, Park, YJ, Tortorici, MA, Wall, A, McGuire, AT, Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281\u201392.","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"2025121207121257052_j_dx-2020-0161_ref_038","doi-asserted-by":"crossref","unstructured":"Du, L, He, Y, Zhou, Y, Liu, S, Zheng, B-J, Jiang, S. The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226\u201336.","DOI":"10.1038\/nrmicro2090"},{"key":"2025121207121257052_j_dx-2020-0161_ref_039","doi-asserted-by":"crossref","unstructured":"Imai, M, Iwatsuki-Horimoto, K, Hatta, M, Loeber, S, Halfmann, PJ, Nakajima, N, et al.. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 2020;117:16587\u201395.","DOI":"10.1073\/pnas.2009799117"},{"key":"2025121207121257052_j_dx-2020-0161_ref_040","doi-asserted-by":"crossref","unstructured":"Sun, J, Zhuang, Z, Zheng, J, Li, K, Wong, RL, Liu, D, et al.. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 2020;182:734\u201343.e5.","DOI":"10.1016\/j.cell.2020.06.010"},{"key":"2025121207121257052_j_dx-2020-0161_ref_041","doi-asserted-by":"crossref","unstructured":"Wang, P, Liu, L, Nair, MS, Yin, MT, Luo, Y, Wang, Q, et al.. SARS-CoV-2 Neutralizing antibody responses are more robust in patients with severe disease. Emerg Microb Infect 2020;9:2091\u201393.","DOI":"10.1101\/2020.06.13.150250"},{"key":"2025121207121257052_j_dx-2020-0161_ref_042","doi-asserted-by":"crossref","unstructured":"Del Fante, C, Franchini, M, Baldanti, F, Percivalle, E, Glingani, C, Marano, G, et al.. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion 2020 Nov 24. https:\/\/doi.org\/10.1111\/trf.16208 [Epub ahead of print].","DOI":"10.1111\/trf.16208"},{"key":"2025121207121257052_j_dx-2020-0161_ref_043","doi-asserted-by":"crossref","unstructured":"Mekonnen, D, Mengist, HM, Derbie, A, Nibret, E, Munshea, A, He, H, et al.. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: a systematic review and meta-analysis. Rev Med Virol 2020 Nov 5. https:\/\/doi.org\/10.1002\/rmv.2181 [Epub ahead of print].","DOI":"10.1002\/rmv.2181"},{"key":"2025121207121257052_j_dx-2020-0161_ref_044","doi-asserted-by":"crossref","unstructured":"Mazzini, L, Martinuzzi, D, Hyseni, I, Benincasa, L, Molesti, E, Casa, E, et al.. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods 2020;27:112937.","DOI":"10.1101\/2020.08.10.243717"},{"key":"2025121207121257052_j_dx-2020-0161_ref_045","doi-asserted-by":"crossref","unstructured":"Padoan, A, Bonfante, F, Pagliari, M, Bortolami, A, Negrini, D, Zuin, S, et al.. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020;62:103101.","DOI":"10.1016\/j.ebiom.2020.103101"},{"key":"2025121207121257052_j_dx-2020-0161_ref_046","doi-asserted-by":"crossref","unstructured":"Bal, A, Pozzetto, B, Trabaud, M-A, Escuret, V, Rabilloud, M, Langlois-Jacques, C, et al.. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild COVID-19 patients: sensitivity, specificity and association with virus neutralization test. medRxiv 2020;09:20194290. https:\/\/doi.org\/10.1101\/2020.09.30.20194290.","DOI":"10.1101\/2020.09.30.20194290"},{"key":"2025121207121257052_j_dx-2020-0161_ref_047","doi-asserted-by":"crossref","unstructured":"von Rhein, C, Scholz, T, Henss, L, Kronstein-Wiedemann, R, Schwarz, T, Rodionov, RN, et al.. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods 2020;288:114031.","DOI":"10.1016\/j.jviromet.2020.114031"},{"key":"2025121207121257052_j_dx-2020-0161_ref_048","doi-asserted-by":"crossref","unstructured":"Apolone, G, Montomoli, E, Manenti, A, Boeri, M, Sabia, F, Hyseni, I, et al.. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori 2020;11:300891620974755.","DOI":"10.1177\/0300891620974755"},{"key":"2025121207121257052_j_dx-2020-0161_ref_049","doi-asserted-by":"crossref","unstructured":"Duan, K, Liu, B, Li, C, Zhang, H, Yu, T, Qu, J, et al.. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117:9490\u20136.","DOI":"10.1073\/pnas.2004168117"},{"key":"2025121207121257052_j_dx-2020-0161_ref_050","doi-asserted-by":"crossref","unstructured":"Li, L, Zhang, W, Hu, Y, Tong, X, Zheng, S, Yang, J, et al.. Effect of convalescent plasma\u00a0therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460\u201370.","DOI":"10.1001\/jama.2020.12607"},{"key":"2025121207121257052_j_dx-2020-0161_ref_051","doi-asserted-by":"crossref","unstructured":"Xia, X, Li, K, Wu, L, Wang, Z, Zhu, M, Huang, B, et al.. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020;136:755\u20139.","DOI":"10.1182\/blood.2020007079"},{"key":"2025121207121257052_j_dx-2020-0161_ref_052","doi-asserted-by":"crossref","unstructured":"Chen, Y, Chen, G, Chui, CH, Lau, FY, Chan, PKS, Ng, MHL, et al.. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293:1450\u20131.","DOI":"10.1001\/jama.293.12.1450-c"},{"key":"2025121207121257052_j_dx-2020-0161_ref_053","doi-asserted-by":"crossref","unstructured":"Wu, BB, Gu, DZ, Yu, JN, Yang, J, Wang-Qin, S. Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis. Infect Genet Evol 2020;84:104485.","DOI":"10.1016\/j.meegid.2020.104485"},{"key":"2025121207121257052_j_dx-2020-0161_ref_054","doi-asserted-by":"crossref","unstructured":"Franchini, M, Glingani, C, Del Fante, C, Capuzzo, M, Di Stasi, V, Rastrelli, G, et al.. The protective effect of O blood type against SARS-CoV-2 infection. Vox Sang 2020 Sep 19. https:\/\/doi.org\/10.1111\/vox.13003 [Epub ahead of print].","DOI":"10.1111\/vox.13003"},{"key":"2025121207121257052_j_dx-2020-0161_ref_055","doi-asserted-by":"crossref","unstructured":"Guillon, P, Cl\u00e9ment, M, S\u00e9bille, V, Rivain, JG, Chou, CF, Ruvo\u00ebn-Clouet, N, et al.. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008;18:1085\u201393.","DOI":"10.1093\/glycob\/cwn093"},{"key":"2025121207121257052_j_dx-2020-0161_ref_056","doi-asserted-by":"crossref","unstructured":"Focosi, D. Anti-A Isohemagglutinin titers and SARS-CoV2 neutralization: implications for children and convalescent plasma selection. Br J Haematol 2020;190:e148-50.","DOI":"10.1111\/bjh.16932"},{"key":"2025121207121257052_j_dx-2020-0161_ref_057","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan, JM, Ward, S, Fogarty, H, O\u2019Donnell, JS. More on \u2019Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol 2020;190:27\u20138.","DOI":"10.1111\/bjh.16845"},{"key":"2025121207121257052_j_dx-2020-0161_ref_058","doi-asserted-by":"crossref","unstructured":"Piazza, G, Morrow, DA. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA 2020;324:2548\u20139.","DOI":"10.1001\/jama.2020.23422"},{"key":"2025121207121257052_j_dx-2020-0161_ref_059","doi-asserted-by":"crossref","unstructured":"Franchini, M, Mannucci, PM. ABO blood group and thrombotic vascular disease. Thromb Haemostasis 2014;112:1103\u20139.","DOI":"10.1160\/th14-05-0457"},{"key":"2025121207121257052_j_dx-2020-0161_ref_060","doi-asserted-by":"crossref","unstructured":"Reilly, JP, Meyer, NJ, Shashaty, MG, Anderson, BJ, Ittner, C, Dunn, TG, et al.. The ABO Histo-Blood Group, endothelial activation, and acute respiratory distress syndrome risk in critical illness. J\u00a0Clin Invest 2020;131:e139700.","DOI":"10.1172\/JCI139700"},{"key":"2025121207121257052_j_dx-2020-0161_ref_061","doi-asserted-by":"crossref","unstructured":"Rizzo, AN, Schmidt, EP. ABO Blood Type: a window into the genetics of acute respiratory distress syndrome susceptibility. J\u00a0Clin Invest 2020;3:144075. https:\/\/doi.org\/10.1172\/JCI144075.","DOI":"10.1172\/JCI144075"},{"key":"2025121207121257052_j_dx-2020-0161_ref_062","doi-asserted-by":"crossref","unstructured":"Ellinghaus, D, Degenhardt, F, Bujanda, L, Buti, M, Albillos, A, Invernizzi, P, et al.. Severe covid-19 GWAS group. Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med 2020;383:1522\u201334.","DOI":"10.1056\/NEJMoa2020283"},{"key":"2025121207121257052_j_dx-2020-0161_ref_063","doi-asserted-by":"crossref","unstructured":"Golinelli, D, Boetto, E, Maietti, E, Fantini, MP. The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. PloS One 2020;15:e0239508. https:\/\/doi.org\/10.1371\/journal.pone.0239508.","DOI":"10.1371\/journal.pone.0239508"},{"key":"2025121207121257052_j_dx-2020-0161_ref_064","doi-asserted-by":"crossref","unstructured":"Casadevall, A, Pirofski, L. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545\u20138.","DOI":"10.1172\/JCI138003"},{"key":"2025121207121257052_j_dx-2020-0161_ref_065","doi-asserted-by":"crossref","unstructured":"Van Erp, EA, Luytjes, W, Ferwerda, G, Van Kasteren, PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol 2019;10:548.","DOI":"10.3389\/fimmu.2019.00548"},{"key":"2025121207121257052_j_dx-2020-0161_ref_066","doi-asserted-by":"crossref","unstructured":"Gunn, BM, Yu, W-H, Karim, MM, Brannan, JM, Herbert, AS, Wec, AZ, et al.. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell Host Microbe 2018;24:221\u201333.e5.","DOI":"10.1016\/j.chom.2018.07.009"},{"key":"2025121207121257052_j_dx-2020-0161_ref_067","doi-asserted-by":"crossref","unstructured":"Abe, Y, Horiuchi, A, Miyake, M, Kimura, S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5\u201319.","DOI":"10.1111\/j.1600-065X.1994.tb00854.x"},{"key":"2025121207121257052_j_dx-2020-0161_ref_068","doi-asserted-by":"crossref","unstructured":"Lutz, HU, Sp\u00e4th, PJ. Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation. Clin Rev Allergy Immunol 2005;29:207\u201312.","DOI":"10.1385\/CRIAI:29:3:207"},{"key":"2025121207121257052_j_dx-2020-0161_ref_069","doi-asserted-by":"crossref","unstructured":"Garraud, O, Heshmati, F, Pozzetto, B, Lefrere, F, Girot, R, Saillol, A, et al.. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol 2016;23:39\u201344.","DOI":"10.1016\/j.tracli.2015.12.003"},{"key":"2025121207121257052_j_dx-2020-0161_ref_070","doi-asserted-by":"crossref","unstructured":"Salazar, E, Perez, KK, Ashraf, M, Chen, J, Castillo, B, Christensen, PA, et al.. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol 2020;190:1680\u201390.","DOI":"10.1016\/j.ajpath.2020.05.014"},{"key":"2025121207121257052_j_dx-2020-0161_ref_071","doi-asserted-by":"crossref","unstructured":"Olivares-Gazca, JC, Priesca-Mar\u00edn, JM, Ojeda-Laguna, M, Garces-Eisele, J, Soto-Olvera, S, Palacios-Alonso, A, et al.. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin 2020;72:159\u201364.","DOI":"10.24875\/RIC.20000237"},{"key":"2025121207121257052_j_dx-2020-0161_ref_072","doi-asserted-by":"crossref","unstructured":"Huang, S, Shen, C, Xia, C, Huang, X, Fu, Y, Tian, L. A retrospective study on the effects of convalescent plasma therapy in 24 patients diagnosed with COVID-19 pneumonia in February and March 2020 at 2 Centers in Wuhan, China. Med Sci Monit 2020;26:e928755.","DOI":"10.12659\/MSM.928755"},{"key":"2025121207121257052_j_dx-2020-0161_ref_073","doi-asserted-by":"crossref","unstructured":"Yang, L, Jin, J, Luo, W, Gan, Y, Chen, B, Li, W. Risk factors for predicting mortality of COVID-19 patients: a systematic review and meta-analysis. PloS One 2020;15:e0243124.","DOI":"10.1371\/journal.pone.0243124"},{"key":"2025121207121257052_j_dx-2020-0161_ref_074","doi-asserted-by":"crossref","unstructured":"Cheng, MH, Zhang, S, Porritt, RA, Arditi, M, Bahar, I. An insertion unique to SARS-CoV-2 exhibits superantigen character strengthened by recent mutations. BiorXiv 2020 May 21. https:\/\/doi.org\/10.1101\/2020.05.21.109272 [Epub ahead of print].","DOI":"10.1101\/2020.05.21.109272"},{"key":"2025121207121257052_j_dx-2020-0161_ref_075","doi-asserted-by":"crossref","unstructured":"Bandopadhyay, P, D\u2019Rozario, R, Lahiri, A, Sarif, J, Ray, Y, Paul, SR, et al.. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv 2020;09:20199109. https:\/\/doi.org\/10.1101\/2020.09.21.20199109.","DOI":"10.1101\/2020.09.21.20199109"},{"key":"2025121207121257052_j_dx-2020-0161_ref_076","doi-asserted-by":"crossref","unstructured":"Dobesh, PP, Trujillo, TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy 2020;40:1130\u201351.","DOI":"10.1002\/phar.2465"},{"key":"2025121207121257052_j_dx-2020-0161_ref_077","doi-asserted-by":"crossref","unstructured":"Liumbruno, GM, Marano, G, Grazzini, G, Capuzzo, E, Franchini, M. Solvent\/detergent-treated plasma: a tale of 30 years of experience. Expet Rev Hematol 2015;8:367\u201374.","DOI":"10.1586\/17474086.2015.1016906"},{"key":"2025121207121257052_j_dx-2020-0161_ref_078","doi-asserted-by":"crossref","unstructured":"Zhang, Y, Xiao, M, Zhang, X, Xia, P, Cao, W, Jiang, W, et al.. Coagulopathy and anti-phospholipid antibodies in patients with COVID-19. N Engl J Med 2020;382:e38.","DOI":"10.1056\/NEJMc2007575"}],"container-title":["Diagnosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2020-0161\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2020-0161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:57:44Z","timestamp":1765526264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2020-0161\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,11,25]]}},"alternative-id":["10.1515\/dx-2020-0161"],"URL":"https:\/\/doi.org\/10.1515\/dx-2020-0161","relation":{},"ISSN":["2194-8011","2194-802X"],"issn-type":[{"value":"2194-8011","type":"print"},{"value":"2194-802X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}